Introduction: A growing body of evidence has suggested that low-frequency or rare coding variants might have strong effects on the development and prognosis of cancer. Here, we aim to assess the role of low-frequency and rare coding variants in the survival of NSCLC in Chinese populations.
Results: A low-frequency missense variant in chaperonin containing TCP1 subunit 6A gene (CCT6A) (rs33922584: adjusted hazard ratio [HR adjusted ] ¼ 1.75, p ¼ 6.06 Â 10 -4 ) was significantly related to the survival of patients with NSCLC, which was further replicated by the TCGA samples (HR adjusted ¼ 4.19, p ¼ 0.015). Interestingly, the G allele of rs33922584 was significantly associated with high expression of CCT6A (p ¼ 0.019) that might induce the worse survival in the TCGA samples (HR adjusted ¼ 1.15, p ¼ 0.047). Besides, rs117512489 in gene phospholipase B1 gene (PLB1) (HR ¼ 2.02, p ¼ 7. 28 Â 10 -4 ) was also associated with survival of the patients with NSCLC in our samples, but it was supported only by gene expression analysis in the TCGA (HR adjusted ¼ 1.15, p ¼ 0.023). Gene-based and pathway-based analysis revealed a total of 32 genes, including CCT6A and 34 potential pathways might account for the survival of NSCLC, respectively.
Introduction
Lung cancer, predominantly NSCLC, is the leading cause of cancer-related death, with about 1.6 million deaths worldwide in 2012. 1 Although progress in the treatment of lung cancer has been made in recent years, the 5-year survival rate in the People's Republic of China is only 17.5%. 2 The genetic background of patients may be involved in drug metabolism and therapeutic response, thus contributing to different prognosis. In the previous studies, genetic variants had been proved to be an effective complementary approach to guide targeted treatment and predict clinical outcomes of patients with NSCLC. 3, 4 Moreover, comprehensive analysis of genetic bias can also identify pivotal genes and pathways that influence the progression and metastasis of tumors. 5 Genome-wide association studies (GWAS), or the candidate gene approach, has identified a subset of germline genetic variations that may contribute to the outcomes of NSCLC and act as potential biomarkers for the prognosis of patients with NSCLC. [6] [7] [8] [9] However, such studies mainly focus on common proxy single-nucleotide polymorphisms (SNPs), which generally occur at a high frequency in populations (usually with a minor allele frequency [MAF] >0.05) with only a modest effect (usually with hazard ratios [HRs] of 1.1-1.4 for risk alleles). Recently, researchers have realized that the identified common variants have accounted for only a fraction of heritability and the remaining "missing heritability" might be partially explained by low-frequency (defined here as a MAF of 0.5%-5%) or rare (MAF <0.5%) variants that had been considered to have strong effects and also contribute to the progression of cancer. 10, 11 Even though a few studies have tried to identify the associations of highly and moderately penetrant rare variants with cancer prognosis, 12 ,13 the effect of rare and low-frequency variants on survival of NSCLC has remained unclear.
In the past few years, the Illumina HumanExome BeadChip (exome chip) (Illumina, San Diego, CA), which focuses mainly on low-frequency or rare variants in coding regions, has been validated as an effective supplementary way to determine the genetic basis of complex diseases. [14] [15] [16] Unlike traditional GWAS studies, the exome chip mainly focused on missense or splice site variants in exons, which usually influence the sequences or structures of proteins directly. Our previous study using the exome chip successfully identified three low-frequency coding variants at 6p21.33 and 20q11.21 that were associated with lung cancer risk in Chinese populations in a three-stage study. 17 From the cases involved in the aforementioned study, 17 we successfully collected the clinical and follow-up information on 1008 patients with NSCLC. In this study, we systematically evaluated the association of rare and low-frequency coding variants from the exome chip with survival of patients with NSCLC; moreover, to increase the reliability of our study, results from The Cancer Genome Atlas (TCGA) database were used to validate our findings.
Materials and Methods

Study Population
We consecutively recruited 2223 patients with a lung-occupying lesion that had been detected by computed tomography screening at the Cancer Hospital of Jiangsu Province and the First Affiliated Hospital of Nanjing Medical University between July 2003 and December 2009. And after histopathological or cytological diagnoses by two local pathologists, 1619 patients with lung cancer were confirmed, including 1380 with NSCLC and 239 with SCLC. After DNA quality control (QC), samples from 1341 patients with NSCLC were tested by Illumina HumanExome Beadchip genotyping, as described in our previous study. 17 Patients with a prior history of other cancers or previous chemotherapy or radiotherapy were excluded. After written informed consent was obtained, we collected 5 mL of venous blood from the patients and conducted a face-to-face interview concerning demographic data (e.g., age and sex) and life style information (e.g., smoking) at recruitment.
Furthermore, we reviewed patients' medical record to gather more detailed clinical information such as date of diagnosis, surgery status, histopathological type, clinical stage, and treatment. All patients were followed up every 3 months by personal or family telephone contacts from the time of enrollment until death or last time of follow-up (last follow-up in August 2013). The follow-up data included comorbidities, clinical examination (radiography, computed tomography, magnetic resonance imaging, and bone scanning) results, treatment information (chemotherapy or radiotherapy), recurrence or metastasis, and survival status (alive or dead, time of death, and cause of death), and the latest medical records were also checked as a complement. Finally, a total of 1008 patients (75.17%) who had both available follow-up and clinical information were enrolled in this study.
The study was performed in accordance with guidelines outlined in the Declaration of Helsinki and approved by the institutional review board of Nanjing Medical University (FWA00001501). Genomic DNA was isolated from leukocyte pellets of venous blood by proteinase K digestion and extracted with phenolchloroform.
QC
The 1008 patients with NSCLC were successfully genotyped by using the Illumina HumanExome Beadchip system with a total of 247,870 variants. Genotypes were called by Illumina GenomeStudio software, and cluster plots were manually checked as necessary. Unqualified genetic variants and samples were filtered from the raw genotyping data through a systematic QC workflow as described previously (Fig. 1) . 17 Briefly, SNPs were excluded from the subsequent analysis if they were duplicated on the chip, located out of the autosomes, had April 2017 2p23.2 and 7p11.2 Coding and NSCLC Survivalan extremely low call rate (<95%), deviated from Hardy-Weinberg equilibrium (p < 1 Â 10 À4 ), or were monomorphic in our study subjects. Samples were also excluded if they had a poor genotyping quality (<95%), showed familial relationships (PI_HAT > 0.25), or had an extreme heterozygosity rate (more than 6 SDs from the mean). As a result, a total of 189,967 variants and one sample were removed from our analysis. Principal component analysis was used to detect population outliers and stratification. As shown in Supplementary  Figure 1 , all samples were matched with the Han Chinese in Beijing, China, and Japanese in Tokyo, Japan, populations of HapMap. We assessed genotyping consistency on the basis of 37 replicate samples and found an overall concordance rate of 99.98%. Moreover, 617 subjects with 6660 overlapping variants were also scanned by using an Affymetrix Genome-Wide Human SNP Array 6.0 in our previous GWAS 18 ; the concordance rate was 99.92% after QC. Accordingly, six samples and 50 variants with a concordance rate less than 95% were further excluded. Finally, 57,903 of 247,870 variants (23.4%) in 1001 cases were retained for further analysis.
Promising SNPs Selection
Exome-wide association analyses were performed by assuming an additive model adjusting for age, sex, stage, histological type, smoking status, operation states, chemotherapy or radiotherapy, and the top principal component. However, at the discovery stage, we did not find any variants associated with the survival of lung cancer at our predefined exome-wide significance level of p less than 8.64 Â 10 -7 (0.05/57,903 variants) ( Supplementary Fig. 2 ). We further annotated variants by using the dbNSFP database and documentation files obtained from the Illumina Product Support Files and focused on SNPs that were annotated as nonsynonymous or splice sites, which potentially had directly biological function by changing amino acid sequence or alternative splicing. Even though the sample size of our study is relatively large for survival analysis compared with Figure 1 . Summary of the study design and work flow. GWAS, genome-wide association studies; TCGA, The Cancer Genome Atlas; PLB1, phospholipase B1 gene; HR, hazard ratio; CCT6A, chaperonin containing TCP1 subunit 6A gene.
those of previous GWAS studies, the power to detect rare or low-frequency variants was still insufficient. In consideration of this, we further relaxed our threshold at a p value less than 1 Â 10 -3 . As a result, a total of 49 SNPs with clear cluster plots (i.e., the quality of SNP was credible in the chip) meeting the aforementioned criteria were selected for a fast-track replication (Supplementary Table 1 ) with the TCGA data.
Replication Analysis by Using the TCGA Database
For exome-wide study, independent validation was an effective approach to reduce false-positive associations. In reality, however, it was difficult to collect enough samples with both detailed clinical information and long-term follow-up. The TCGA database, which contains various types of genomic data and systematic clinical information on a wide variety of cancers (including lung cancer), can provide a highly costeffective validation for our study, although potential association might be lost because of heterogeneity. Thus, we downloaded the clinical and follow-up information for patients in the TCGA. The level 3 expression data from RNA sequencing (expectation-maximization normalized read counts) were obtained for tumors and the matched normal lung tissues for lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD). The original genotype data (level 2) of the same subjects with LUSC and LUAD were applied and approved in February 2015. The open access somatic mutations of critical driver genes (EGER, KRAS, and anaplastic lymphoma receptor tyrosine kinase gene [ALK]) in LUSC and LUAD were derived from the annotated somatic mutation MAF file of the TCGA in August 2016. After integrating the aforementioned data sets, we finally obtained 773 samples (369 LUSC and 404 LUAD) with complete clinical information, gene expression matrix, and genotype data. To further increase the genome coverage of the genotype data, we also performed a two-step imputation analyses (prephasing and imputation).
As only some of the 49 SNPs were imputed with credible quality (defined as info ! 0.5), 17, [19] [20] [21] and with the knowledge of nonsynonymous or splice site variants usually exerting their biological function by influencing the host genes, we validated the promising variants by using both the imputed genotype data directly and the expression data of host genes indirectly (see Fig. 1 ). The expression levels of genes were classified into four groups according to quartile, and the lowest one was set as the reference. Multivariate Cox regression models were used to evaluate the effect of SNPs and gene expression on NSCLC survival by adjusting for age, sex, smoking, stage, and histological type. Variants validated by either the consistent associations from genotype or expression data of the TCGA were considered to be significantly associated SNPs and reported in our study.
Gene and Pathway-Based Analysis
To integrate results in a more comprehensive way, we also performed a gene-based analysis that included all variants annotated as nonsynonymous or splice sites. Finally, a total of 40,837 variants within 8146 genes were analyzed in our study. The R package coxKM was used in our gene-based analysis, which was designed for conducting SNP set association tests for right-censored survival outcomes on the basis of a kernel machine Cox regression framework. 22 Then, we evaluated whether the potentially associated genes were enriched in particular pathways. ARTP, an R package for analyzing predefined genetic pathways on the basis of a genetic association study, was used to combine the effects of genes within the same pathway. 23 The p values derived from the gene-based analysis in our study (SNP set analysis) were used in the pathway analysis. The predefined pathways were accessed from the Molecular Signatures Database (version 5.0) website (http://www.broadinstitute.org/gsea/msigdb). This study contained the pathways defined by BioCarta, Kyoto Encyclopedia of Genes and Genomes, GO, Chemical and Genomic Perturbations, Reactome, MicroRNA Targets, and Transcription Factor Targets. To further confirm the promising associations, the expression data from the TCGA were also used to validate the identified genes and pathways. In the gene-and pathway-based analysis, only associations with a p value less than 0.05 in both our data and those from the TCGA were considered significant.
Statistical Analysis
The primary end point was lung cancer-specific death. Patients who were alive, were lost to follow-up, or died of other causes at the last observation were considered censored. Additionally, overall survival was defined as the time from diagnosis to death or latest follow-up. HRs and their 95% confidence intervals were calculated by multivariate Cox regression analyses as already described. The log-rank test was used to compare the survival time across different subgroups categorized by patients' characteristics or clinical features. The Wilcoxon rank-sum test was done to evaluate the association of the expression of potentially associated genes with patients' characteristics or clinical features. PLINK 1.07 the "survival" package in R were used for generally exomewide statistical analysis. At the discovery stage, we carried out principal component analysis on the basis of 4604 autosomal ancestry informative markers that were included on the exome chips to determine ancestry and population stratification by using EIGENSOFT. 24 Conditional analysis was applied to test the independence of genetic variants in each region by using the identified variants as covariates. SHAPEIT 1.0 (haplotype estimation step) and IMPUTE2 (genotype imputation step) were used to impute the ungenotyped SNPs of the TCGA samples, and haplotype information from the 1000 Genomes Project (phase I integrated variant set across all 1092 individuals, version 3 [released in May 2012]) was used as the reference. A quantile-quantile (Q-Q) plot was generated by using R 3.1.3. A regional plot was generated by using an online tool, LocusZoom, version 1.1. ANNOVAR was used to annotate variants according to GENCODE, version 7, coding transcripts, dbNSFP or documentation files obtained from the Illumina Product Support Files.
Results
Patients' Characteristics and Clinical Features
The characteristics of our study's patients with NSCLC are shown in Table 1 . The median survival time was 26.02 months, and 545 patients in our cohort (54.4%) died of lung cancer. We found that sex, smoking, surgical operation status, clinical stage, and chemotherapy or radiotherapy were significantly associated with the survival of our subjects with NSCLC. The clinical features and mutation status of driver genes from the TCGA are summarized in Supplementary Table 2 .
Single-Variant Analysis
After QC, a total of 57,903 variants in 1001 cases were included in the subsequent analyses. In the single-variant analysis, the Q-Q plot revealed a good match between the distributions of the observed and expected p values (Supplementary Fig. 3) . A small genomic control inflation factor (l) of 1.03 indicated a low possibility of false-positive associations resulting from population stratification. However, we did not find any variant associated with survival of patients with lung cancer at our predefined exomewide significance level (8.64 Â 10 -7 ) ( Supplementary   Fig. 2 ), which was probably due to limited statistical power. Then, we focused on potentially functional variants and selected 49 variants with p less than 1 Â 10 -3 for further replication with the imputed genotype data of the TCGA (Supplementary Table 1) ; however, only 15 SNPs(30.6%) were imputed qualifiedly (info ! 0.5). As shown in Table 2 , rs33922584 (encoding chaperonin ( Fig. 2A and C) . We further tested the associations between the expression levels of the 49 host genes and survival of patients with lung cancer in parallel. As a result, we found that the expression of CCT6A was significantly associated with patients' survival (HR ¼ 1.15, p ¼ 0.047) (Supplementary Fig. 4A ) and the G allele of rs33922584 was significantly associated with high expression of CCT6A (p ¼ 0.019) in the TCGA (Fig. 2D) . Meanwhile, we compared the differences in CCT6A expression across patients' characteristics or clinical features and found that CCT6A expression was significantly associated with sex, smoking, clinical stage, and histological type in the TCGA. Interestingly, the high expression of another gene, phospholipase B gene (PLB1), was also related with worse survival of patients (HR ¼ 1.15, p ¼ 0.023) in the TCGA (Supplementary Fig. 4B [ Supplementary Fig. 5A] ), whereas the difference in expression was not obvious for PLB1 (57.0%, p ¼ 0.295 [ Supplementary Fig. 5B ]) on the basis of the TCGA. Furthermore, we also evaluated the effect of genetic variants in the flanking regions (1 megabase upstream or downstream) of rs33922584 and rs117512489 on lung cancer survival but found no variant with lower p values or in strong linkage disequilibrium (LD) with these two variants ( Supplementary Fig. 6 and Supplementary Table 3 ). Then, we conducted a stratification analysis for the two identified SNPs by age, sex, smoking, surgical operation, clinical stage, histological type, and chemotherapy/radiotherapy and did not find significant heterogeneity between the different subgroups (Supplementary Table 4 ).
Gene-Based Analysis
We conducted a gene-based analysis that included all nonsynonymous or splice site variants using the coxKM package and then examined the associations between the expression of promising genes and patients' survival in the TCGA. We found that kinase suppressor of ras 2 gene (KSR2) was the most significant gene (p ¼ 2 Â 10 -4 ) in 1001 patients with NSCLC; however, we did not confirm such findings in the TCGA data set (p ¼ 0.203). Moreover, a total of 32 genes proved to be significantly associated with survival of patients with NSCLC both in our data set and in the TCGA (Supplementary Table 5 ). The gene CCT6A identified by the single-variant analysis was also significant in the gene-based analysis (p ¼ 0.005), but PLB1 was not replicated in the genebased analysis. Among the 32 identified genes, period circadian clock 1 gene (PER1), deleted in lung and esophageal cancer 1 gene (DLEC1), F2R like thrombin/ trypsin receptor 3 gene (F2RL3), and patched 1 gene (PTCH1) had been associated with survival of patients with lung cancer through different mechanisms [25] [26] [27] [28] and polo like kinase 4 (PLK4) was demonstrated to be implicated in mitotic and cancer development. 29 However, the roles of remaining genes in the progression of NSCLC were not reported before. 
Pathway-Based Analysis
We also performed a pathway-based analysis using ARTP to combine the effect of genes within the same pathway. A total of 34 candidate pathways were shown to be associated with survival of patients with NSCLC (p < 0.05) and confirmed by the TCGA (Supplementary  Tables 5 and 6) , and the five top-ranked pathways (p < 0.01 in our data), including the Firestein catenin beta 1 gene (CTNNB1) pathway (mainly containing genes required for CTNNB1 activity in colon cancer), 30 Whitfield cell cycle G2-M pathway (usually including genes expressed with peak during the G2/M phase of cell cycle), 31 Zhang antiviral response to ribavirin up pathway (primarily covering genes up-regulated in A549 cells upon infection with respiratory syncytial virus (RSV) and up-regulated by further treatment with ribavirin), 32 Dacosta ERCC excision repair 3, TFIIH core complex helicase subunit gene (ERCC3) allele XPCS vs TTD up pathway (mainly including genes up-regulated in fibroblasts expressing different mutant forms of ERCC3), 33 and Sweet KRAS targets up pathway (usually containing genes up-regulated in KRAS knockdown human cell line) (Fig. 3) . 34 Moreover, several other pathways of particular interest (p < 0.05 in our data) included the Mantovani nuclear factor kappa B gene (NFKB) targets DN pathway (including nuclear factor k B-controlled genes in endothelial cells that were down-regulated in response to viral G protein-coupled receptor protein), 35 Kyoto Encyclopedia of Genes and Genomes p53 signaling pathway (classic p53 signaling pathway), Falvella smokers with lung cancer pathway (containing genes that distinguished normal from lung adenocarcinoma samples and smokers from nonsmoking subjects), 36 Ding lung cancer by mutation rate pathway (including genes mutated at significantly high frequencies in lung adenocarcinoma), 37 and Amundson poor survival after gamma radiation 8G pathway (covering genes correlated with poor survival after 8 Gy of g irradiation in 60 cell lines of the National Cancer Institute Anticancer Drug Screen). 38 
Discussion
In this study, we investigated the associations between exome-wide low-frequency or rare genetic variants and the outcomes of patients in the People's Republic of China with NSCLC. When the biological, bioinformatics, and statistical evidence are incorporated, two missense variants rs33922584 (encoding p.Tyr229Cys of CCT6A) and rs117512489 (encoding p.Arg1100Gln of PLB1) might be independent prognostic factors for the overall survival of patients with NSCLC. Further gene-based and pathway-based analysis suggested that some genes represented by CCT6A (CCT6A, PER1, DLEC1, F2RL3, PTCH1, and PLK4) and several critical pathways, such as CTNNB1, cell cycle, antiviral response to ribavirin, ERCC3, KRAS, tumor protein p53 gene (TP53), NFKB, lung cancer mutation rate, and gamma irradiation related pathway, might be promising risk factors for the prognosis of NSCLC. These findings highlighted the importance of low-frequency and rare coding variants in survival of patients with NSCLC and identified critical genes and pathways that are involved in the progression of NSCLC.
CCT6A encodes a molecular chaperone that is a member of the chaperonin containing TCP1 complex (CCT), also known as the TCP1 ring complex. This complex can assist in the folding of proteins upon adenosine triphosphate hydrolysis, participate in the repair of damaged proteins, and assist proteins in membrane translocation. Differential modulation of chaperone activity might alter the half-life of several proteins that, in turn, may affect the sensitivity of tumor cells to chemotherapy. 39 Tanic et al., found that CCT6A was differentially expressed in a human melanoma cell line and its drug-resistant variants. 39 These findings indicated that CCT6A was probably involved in the sensitivity to therapy of lung cancer. In this study, we found that both rs33922584 on the sixth exon of CCT6A and CCT6A per se were associated with survival of patients with NSCLC in both single-variant and gene-based analysis in our study, which was further validated by the TCGA data. The variant (A / G) of rs33922584 can result in an amino acid alteration from tyrosine 13 to April 2017 2p23.2 and 7p11.2 Coding and NSCLC Survivalcysteine (Cys), and such substitution is predicted to be "deleterious" according to a likelihood ratio test and MutationTaster algorithms. According to the protein database, this position is also a phosphorylation site and probably involved in posttranslational modification ( Supplementary Fig. 7A ). Moreover, as already described, we also found rs33922584 to probably be an expression quantitative trait locus of CCT6A (Fig. 2D) . On the basis of histone chromatin immunoprecipitation sequencing results from the Roadmap Epigenomics Consortium and ENOCDE project, we found that rs75356442 in perfect LD with rs33922584 (R 2 ¼ 1.0) was located at a region modified by H3K4me1, H3K27ac, and H3K4me3 in the lung carcinoma cell line A549, which was indicated to be a potential promoter and enhancer ( Supplementary  Fig. 8 ). The expression quantitative trait locus between rs33922584 and CCT6A was probably due to this high-LD variant involved in the transcriptional regulation of CCT6A. 40, 41 Even though the expression of CCT6A was significantly associated with smoking status in patients with lung cancer, the frequency of rs33922584 was not influenced by smoking in healthy controls (data not shown). In conclusion, we speculated that the variant rs33922584 might modulate survival of patients with NSCLC by regulating the expression of CCT6A, destroying the protein structure, or influencing the protein phosphorylation. However, the exact biological mechanism needs to be clarified in further studies.
Phospholipase B1 is a secreted membrane-associated phospholipase; it is involved in the choline metabolite in tumors. 42 Inhibiting the phospholipase B activity in MH-S cells had been reported to result in the downregulation of genes involved in phagocytosis and the inflammatory response. 43 In basal-like xenografts of human breast carcinomas, PLB1 was more highly expressed and contributed to the higher concentrations of glycerophosphocholine, which might serve as biomarkers for both diagnostic and treatment monitoring purposes in breast carcinomas. 42 In this study, the lowfrequency variant rs117512489 at 2p23.2 in PLB1 was related to survival of NSCLC in our subjects, which was validated by expression from the TCGA. Rs117512489 was located on the 47th exon of PLB1, resulting in a substitution from arginine 44 to glutamine at site 1100, and the position was predicted to be a potentially disordered region of the protein located at the extracellular topological domain (Supplementary Fig. 7B ).
In the gene-based analysis, we determined that 32 genes, including CCT6A, were significantly associated with survival of patients with lung cancer, which was further validated in the gene expression analysis of the TCGA. Among those genes, DLEC1, F2RL3, PER1, and PTCH1, had been reported as prognostic markers of NSCLC in previous studies. [25] [26] [27] [28] DLEC1 is a well-known tumor suppressor gene; it has been involved in carcinogenesis in the breast, prostate, liver, lung, ovarian, colon, and gastric cancers. [45] [46] [47] [48] [49] In a large populationbased cohort study, hypomethylation at F2RL3 was strongly associated with lung cancer incidence and mortality even after controlling for smoking status. 28 The gene PER1 is a candidate tumor suppressor in lung cancer 50 and lower levels of expression of PER1 were recently proved to be significantly associated with the worse survival of NSCLC.
27 PTCH1 is also a tumor suppressor gene, and mutations of it have been associated with basal cell nevus syndrome, trichoepitheliomas, transitional cell carcinomas of the bladder, and holoprosencephaly. 44, 51 Copy number loss of PTCH1 has been demonstrated to be associated with poor survival in patients with pulmonary squamous cell carcinoma. 26 In this study, we demonstrated that nonsynonymous or splice site variants and expression level of these genes also contributed to the prognosis of patients with NSCLC. These findings might improve our understanding of the mechanisms of NSCLC survival and provide new potentially prognostic markers or therapeutic targets.
In the pathway-based analysis, a total of 34 critical pathways were identified as being associated with survival of patients with lung cancer in both our and the TCGA data sets. Interestingly, most of the pathways identified in our study were from the chemical and genetic perturbations database, 30, 37 which mainly included gene sets representing expression signatures of genetic and chemical perturbations. This suggested that patients' responses to chemical treatment or genetic changes are more likely linked to NSCLC prognosis than classic biologic pathways. The identified 34 pathways involved several different mechanisms perturbed by the change in classic key genes (such as CTNNB1, ERCC3, KRAS, TP53, and NFKB), biological processes (such as cell cycle, apoptosis, senescence, glycogen breakdown, and TNF family), biological system (such as complement system and immune system), and response to specific physiological environment (such as smoking, RSV, and radiation) might together affect survival of patients with NSCLC. We also noticed that certain genes identified by the gene-based analysis, such as PER1, PLK4, protein tyrosine phosphatase, receptor type N gene (PTPRN), glycogen phosphorylase B gene (PYGB), primase (DNA) subunit 1 gene (PRIM1), and ATP binding cassette subfamily C member 6 gene (ABCC6), were included in the 34 identified pathways. Interestingly, the five topranked (p < 0.01) pathways (Firestein CTNNB1 pathway, Whitfield cell cycle G2-M pathway, Zhang antiviral response to ribavirin up pathway, Dacosta ERCC3 allele XPCS vs TTD up pathway, and Sweet KRAS targets up pathway) identified in our data all focused on important genes or pathways that have been implicated in the progress of lung cancer. For example, Firestein CTNNB1 pathway mainly contained genes required for CTNNB1 activity in DLD-1 cells. CTNNB1 encodes b-catenin, which regulates cell-cell adhesion and cell growth, and acts as an intracellular signal transducer in the Wnt signaling pathway. Overexpression of b-catenin has recently been associated with the poor overall survival of stage IA to IIA lung cancer. 52 The cell cycle G2-M is an important checkpoint that prevents cells from entering mitosis, allowing DNA repair to occur and halting the proliferation of damaged cells. Proteins with peak activity during the G2-M phase of cell cycle have usually been implicated in several important biological processes, such as DNA repair. This pathway had been reported to be associated with prognosis of advanced NSCLC in a Chinese population. 53 Zhang antiviral response to ribavirin up pathway mainly covered genes up-regulated in A549 cells upon infection with RSV and up-regulated by further treatment with ribavirin. Human RSV, which belongs to the paramyxovirus family, is an enveloped, nonsegmented, negative-sense, singlestranded RNA virus. RSV was the most common virus involved in lung infection of patients with chemotherapy-induced immune defects. 54 On the other hand, oncolytic characteristics of RSV have also been reported in lung, skin, and prostate cancer cells. [55] [56] [57] Dacosta ERCC3 allele XPCS vs TTD up pathway usually included genes up-regulated in fibroblasts expressing different mutant forms of ERCC excision repair 3, TFIIH core complex helicase subunit. ERCC excision repair 3, TFIIH core complex helicase subunit is one of the major proteins in the nucleotide excision repair pathway, and it plays an important role in DNA damage removal. Platinum compounds such as cisplatin and carboplatin are antineoplastic agents whose cytotoxic effect is attributed to the formation of bulky platinum-DNA adducts. The activity of these DNA repair mechanisms plays a central role in determining sensitivity to platinum compounds, and a high DNA repair capacity has been related to chemoresistance in NSCLC. 58 Sweet KRAS targets up pathway mainly contains genes upregulated in KRAS knockdown human cell line. KRAS is an oncogene that encodes a protein of the small GTPase superfamily. KRAS is one of the most frequently mutated genes in NSCLC, accounting for approximately 25% of all NSCLC tumors. It is widely known that constitutively active signaling downstream of KRAS is a fundamental driver of lung tumorigenesis. The functions of KRAS has been related to cell differentiation, cell growth, apoptosis, cell survival, and cell proliferation. 59 Even though the prognostic significance of KRAS mutation in NSCLC remains debated and directly targeting KRAS is still unavailable, nearly 30% of patients can be benefit from targeting KRAS downstream effectors. 60 Genes involved in the response to the changes in these key genes might be the downstream genes directly or might influence a shared pathway that contributes to the progression of lung cancer.
To our knowledge, this is the first exome-wide association study to investigate the effect of the lowfrequency or rare genetic variants on the prognosis of patients with NSCLC, and the sample size is relatively large compared with those of previous GWAS studies. Additionally, the genotype and expression data from the TCGA were used to provide more evidence, which would largely increase the reliability of our results. The identified novel variants and candidate genes in this study may provide a new insight into the mechanism of therapeutic sensitivity or chemotherapy resistance of patients with lung cancer. Even though the frequency of the identified variants was low, the size of their effect was relative large (rs33922584: HR ¼ 1.86) compared with that of previously reported common variants (usually HR < 1.5), 61, 62 indicating that patients with these variants usually showed worse prognosis. Thus, when patients with lung cancer are identified as having this low-frequency variant by a laboratory test, more frequent follow-up and special medical care might usually be needed. Moreover, germline-based genomic markers (including both common and rare variants), clinical information (such as histological type and stage), and therapeutic methods should be taken into account together with tumor mutation status (e.g., EGFR, KRAS, and ALK mutation status) to build a more comprehensive prediction model in clinical practice. However, several limitations need to be addressed. First, the mixed cohort with surgical patients and nonsurgical patients with both early-stage and advanced-stage might introduce biases even though these factors were adjusted for in the analysis. Second, as the ethnicity and clinical features differed between our samples and those of the TCGA, some potential associated variants or genes might have been missed in this study, but the consistent associations were much more likely to be real. Third, the mutation status of EGFR, which is an important targeted therapy gene in Asians, was not available in our study, and thus we could not conduct a more in-depth analysis for such information. In addition, we failed to investigate the association between genetic variants and other clinical outcomes because of data missing. Lastly, this study focused mainly on providing the support for associations between genetic variants and NSCLC prognosis, but the biological significance of the results remains unclear. Therefore, further functional evaluations and larger studies with more rigorous design (such as taking into account of EGFR mutations status) are warranted to validate our findings.
